Plexium Unveils Groundbreaking Data on Degrader Programs at AACR 2025 Plexium showcased promising findings from their selective degrader programs targeting SMARCA2, IKZF2, and CDK2 at AACR 2025. The developments illustrate their innovative approach to cancer treatment.

Plexium Unveils Groundbreaking Data on Degrader Programs at AACR 2025 #USA #Chicago #Cancer_Research #Plexium #SMARCA2

Fascinating that ATPases SMARCA4 & SMARCA2 are both dysregulated in some rare & aggressive cancers by mutation & epigenetic silencing, respectively. We talk about epigenetic silencing of SMARCA2 & other things here: 10.1016/j.canlet.2024.217282 #SWI/SNF #SMARCA2 #Chromatin #OvarianCancer #SCCOHT

Dual loss of #SMARCA2 & #SMARCA4 is rare. PhD candidate Natisha Field in our gp leads an insightful review in #CancerLetters on poor prognosis malignancies with this loss that impacts on #ChromatinRemodeling. #SWISNF #OvarianCancer #LungCancer #epigenetics. Read here:
10.1016/j.canlet.2024.217282